Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to compare the efficacy (in terms of vein clearance) and safety of Nd:YAG laser combined with injection sclerotherapy versus diode laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias using the Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique.
Reticular veins and telangiectasias (spider veins) represent common chronic venous disorders affecting a large proportion of the adult population, particularly women.
The Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique has emerged as an innovative method combining transdermal laser therapy, injection sclerotherapy, and skin cooling. This multimodal approach enhances visualization of feeder veins using augmented reality or vein illumination systems, allowing precise targeting and improved clearance rates. Cooling reduces pain and protects the epidermis, making the procedure more tolerable and safer.
Nd:YAG laser (1064 nm) is considered the cornerstone of the CLaCS technique due to its deeper penetration and selective photothermolysis of hemoglobin. It effectively targets deeper reticular veins (up to 3-4 mm depth), induces vessel wall contraction, and facilitates subsequent sclerotherapy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A (Nd:YAG Group): | Experimental | Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS). |
|
| Group B (Diode Group) | Experimental | Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nd:YAG laser | Device | Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Degree of vein clearance | Degree of vein clearance will be assessed by immediate endpoint response during laser application, defined as either instantaneous disappearance of the vein or an immediate change in vein color. | 6 months postoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| Degree of pain | Each patient will be instructed about postoperative pain assessment with VAS. VAS (0 represents "no pain" while 10 represents "the worst pain imaginable"). | 6 months postoperatively |
| Degree of patient satisfaction |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mohamed A Hagag, MD | Contact | 00201126560324 | hagagmohamed@med.asu.edu.eg |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ain Shams University | Recruiting | Cairo | 11591 | Egypt |
The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
After the end of study for one year.
The data will be available upon a reasonable request from the corresponding author.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Diode laser | Drug | Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS). |
|
Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).
| 6 months postoperatively |
| Incidence of complications | Incidence of complications such as hyperpigmentation, burns, and matting will be recorded. | 6 months postoperatively |
| Number of treatment sessions required | Number of treatment sessions required will be recorded. | 6 months postoperatively |
| Recurrence rate | Recurrence rate will be recorded. | 6 months postoperatively |
| ID | Term |
|---|---|
| D013684 | Telangiectasis |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D054023 | Lasers, Semiconductor |
| ID | Term |
|---|---|
| D007834 | Lasers |
| D055096 | Optical Devices |
| D004864 | Equipment and Supplies |
| D055618 | Radiation Equipment and Supplies |
Not provided
Not provided